Here are three biotech stocks that recently saw their 50-day moving average cross above the 200-day average, a golden cross, plus two that went the other way.
Despite the wearing down of hepatitis C drugs and the political climate targeting drug prices, this analyst sees stabilization and predictability in the base businesses of two key biotech leaders.
24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new ideas for investors and traders alike. Some of these analyst reports cover stocks to buy,…
CRISPR Therapeutics shares jumped on Tuesday after the firm announced that the FDA has granted Fast Track Designation for its treatment for transfusion-dependent beta thalassemia.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Tuesday included Alcoa, Apple, Autodesk, BB&T, Bed Bath & Beyond, Camping World, Nvidia, Vertex Pharmaceuticals and Voya Financial.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Boeing, Booking, Camping World, Domino's Pizza, iRobot, MetLife, Neogen, Southern Copper, Vertex Pharmaceuticals and Worldpay.
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the first quarter of 2019.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Wednesday included Aflac, Akamai, BioMarin, Caesars Entertainment, CBS, Crocs, GW Pharma, Medtronic, Netflix and Sirius XM.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Apple, Baker Hughes, Biogen, FedEx, Intel, Micron Technology, Roku and Shake Shack.
Here are five top health care stocks that provide investors with different avenues to invest in the sector. They all should be solid additions to growth portfolios for 2019.
CRISPR Therapeutics shares made a handy gain on Thursday after the company announced a key FDA decision concerning its collaboration with Vertex Pharmaceuticals.
Chris Lange Merrill Lynch recently highlighted sectors it considers a good opportunity now that are likely to outperform in the near term, and the sector that rated highest was biotechnology.
A series of new Stifel research reports focus on three biotech companies that have upcoming clinical data that could prove to be huge.
Vertex Pharmaceuticals shares saw a handy gain on Thursday after the FDA gave a nod to Vertex’s cystic fibrosis treatment.
Chris Lange CRISPR Therapeutics shares saw a significant drop on Thursday morning after an announcement that the FDA placed a clinical hold on the Investigational New Drug Application (IND) for CTX001 for the treatment…
Chris Lange 
